Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
Diabetes & Metabolism Journal
;
: 342-347, 2015.
Article
in English
| WPRIM
| ID: wpr-162195
ABSTRACT
BACKGROUND:
Predictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus. The aim of this study is therefore to clarify predictive factors of the efficacy of DPP-4 inhibitors for lowering HbA1c after 12 months of treatment.METHODS:
A total of 191 consecutive type 2 diabetic patients (male sex 55%, mean age, 68.3+/-35.8 years), who had been treated with DPP-4 inhibitors for 12 months, were enrolled in this study and evaluated retrospectively.RESULTS:
After 12 months of DPP-4 inhibitor treatment, random blood glucose level, and HbA1c level, decreased from 167+/-63 to 151+/-49 mg/dL (P<0.01), and from 7.5%+/-1.3% to 6.9%+/-0.9% (P<0.01) respectively, without severe side effects. Multiple regression analysis showed that predictors of DPP-4 inhibitor treatment efficacy in lowering HbA1c level after 12 months were a decrease in HbA1c level after 3 months of treatment, a high baseline HbA1c level, a low baseline body mass index, and the absence of coronary artery disease.CONCLUSION:
Most suitable candidates for treatment with DPP-4 inhibitors are diabetics who are not obese and do not have coronary artery disease. In addition, long-term efficacy of DPP-4 inhibitors can be predicted by decrement of HbA1c after 3 months of treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Blood Glucose
/
Coronary Artery Disease
/
Glycated Hemoglobin
/
Body Mass Index
/
Retrospective Studies
/
Treatment Outcome
/
Diabetes Mellitus
/
Diabetes Mellitus, Type 2
/
Dipeptidyl-Peptidase IV Inhibitors
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Diabetes & Metabolism Journal
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS